CVS to Split Off Drugstore Business, Ending the Bigger-Is-Better Era for Healthcare Conglomerates
Published . Updated .
Key takeaways
- In a breakup planned for 2028, CVS Health intends to keep together its insurance and pharmacy benefits divisions and create a separate company for its pharmacies.
- Exposed: XLV, XBI, XLF, LLY, JNJ
- Market reaction: XLV +2.7% on the day (still updating); XBI +1.6% on the day (still updating); XLF +3.0% on the day (still updating)
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
In a breakup planned for 2028, CVS Health intends to keep together its insurance and pharmacy benefits divisions and create a separate company for its pharmacies.
Directly affected
- CVS Cvs Health-0.7% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “healthcare” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “healthcare” (pharma and health) in this story.
- XLF Financial Select Sector SPDR-1.6% 30d
Financial Select Sector SPDR: it holds insurers. Linked by “insurance” (insurers) in this story.
- LLY Eli Lilly and+22.4% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story.
- JNJ Johnson & Johnson-1.7% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story.
- PFE Pfizer+5.5% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story.
- MRK Merck+1.9% 18d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story.
- CB Chubb+7.3% 30d
Chubb (fire, marine and casualty insurance): insurers pay claims and price policies around events like this. Linked by “insurance” (insurers) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| CVS | -1.68% | -1.33% | base | -11.61% | after close | after close | after close |
| XLV | -2.31% | +0.48% | base | +2.70% | after close | after close | after close |
| XBI | +1.67% | +0.67% | base | +1.61% | after close | after close | after close |
| XLF | -1.85% | -1.14% | base | +3.03% | after close | after close | after close |
| LLY | -8.42% | +0.54% | base | +1.37% | after close | after close | after close |
| JNJ | +1.93% | +2.66% | base | +2.90% | after close | after close | after close |
| PFE | -1.67% | +1.73% | base | +2.02% | after close | after close | after close |
| MRK | -2.47% | +3.37% | base | +2.55% | after close | after close | after close |
| CB | -2.94% | -0.61% | base | +1.68% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
In a breakup planned for 2028, CVS Health intends to keep together its insurance and pharmacy benefits divisions and create a separate company for its pharmacies.
Source: The New York Times
Price since this story was published: Select Sector Spdr Tr (XLV)
| Company | When | Move | Status |
|---|---|---|---|
| Chubb (CB) | that day | +1.68% | still updating |
| Chubb (CB) | three days earlier | -0.61% | final price |
| Chubb (CB) | five days earlier | -2.94% | final price |
| CVS | that day | -11.61% | still updating |
| CVS | three days earlier | -1.33% | final price |
| CVS | five days earlier | -1.68% | final price |
| Johnson & Johnson (JNJ) | that day | +2.90% | still updating |
| Johnson & Johnson (JNJ) | three days earlier | +2.66% | final price |
| Johnson & Johnson (JNJ) | five days earlier | +1.93% | final price |
| Eli Lilly (LLY) | that day | +1.37% | still updating |
| Eli Lilly (LLY) | three days earlier | +0.54% | final price |
| Eli Lilly (LLY) | five days earlier | -8.42% | final price |
| Merck (MRK) | that day | +2.55% | still updating |
| Merck (MRK) | three days earlier | +3.37% | final price |
| Merck (MRK) | five days earlier | -2.47% | final price |
| Pfizer (PFE) | that day | +2.02% | still updating |
| Pfizer (PFE) | three days earlier | +1.73% | final price |
| Pfizer (PFE) | five days earlier | -1.67% | final price |
| Spdr Series Trust (XBI) | that day | +1.61% | still updating |
| Spdr Series Trust (XBI) | three days earlier | +0.67% | final price |
| Spdr Series Trust (XBI) | five days earlier | +1.67% | final price |
| Select Sector Spdr Tr (XLF) | that day | +3.03% | still updating |
| Select Sector Spdr Tr (XLF) | three days earlier | -1.14% | final price |
| Select Sector Spdr Tr (XLF) | five days earlier | -1.85% | final price |
| Select Sector Spdr Tr (XLV) | that day | +2.70% | still updating |
| Select Sector Spdr Tr (XLV) | three days earlier | +0.48% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -2.31% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna sold Cvs Health (CVS) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Cvs Health (CVS) (held by a spouse), worth $1,001 - $15,000 on 24 Aug 2026. That is 72 days before publication. Filed 4 Sep 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 35 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 57 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 75 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 41 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 77 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Chubb (CB), worth $1,001 - $15,000 on 24 Sep 2026. That is 41 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Kevin Hern sold Chubb (CB) (jointly held), worth $1,001 - $15,000 on 23 Sep 2026. That is 42 days before publication. Filed 13 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies mentioned with this story
- XLV Select Sector Spdr Tr
In “CVS to Split Off Drugstore Business, Ending the Bigger-Is-Better Era for Healthcare Conglomerates,” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “healthcare” (pharma and health) in this story
- XBI Spdr Series Trust
Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence in the 4 Nov 2026 story “CVS to Split Off Drugstore Business, Ending the Bigger-Is-Better Era for Healthcare Conglomerates.” Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “healthcare” (pharma and health) in this story
- XLF Select Sector Spdr Tr
Select Sector Spdr Tr (XLF) is linked, with no stored direction, medium confidence in the 4 Nov 2026 story “CVS to Split Off Drugstore Business, Ending the Bigger-Is-Better Era for Healthcare Conglomerates.” Reason on file: Financial Select Sector SPDR: it holds insurers. Linked by “insurance” (insurers) in this story
- LLY Eli Lilly
In “CVS to Split Off Drugstore Business, Ending the Bigger-Is-Better Era for Healthcare Conglomerates,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story
- JNJ Johnson & Johnson
Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence in the 4 Nov 2026 story “CVS to Split Off Drugstore Business, Ending the Bigger-Is-Better Era for Healthcare Conglomerates.” Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story
- PFE Pfizer
Pfizer (PFE) is linked, with no stored direction, medium confidence in the 4 Nov 2026 story “CVS to Split Off Drugstore Business, Ending the Bigger-Is-Better Era for Healthcare Conglomerates.” Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story
- MRK Merck
For “CVS to Split Off Drugstore Business, Ending the Bigger-Is-Better Era for Healthcare Conglomerates,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story
- CB Chubb
For “CVS to Split Off Drugstore Business, Ending the Bigger-Is-Better Era for Healthcare Conglomerates,” Chubb (CB) is linked, with no stored direction, medium confidence. Reason on file: Chubb (fire, marine and casualty insurance): insurers pay claims and price policies around events like this. Linked by “insurance” (insurers) in this story
Select Sector Spdr Tr (XLV)
Select Sector Spdr Tr (XLV) is the company in “CVS to Split Off Drugstore Business, Ending the Bigger-Is-Better Era for Healthcare Conglomerates,” the 4 Nov 2026 this story story.
Select Sector Spdr Tr (XLV) is on the page because Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “healthcare” (pharma and health) in this story
Spdr Series Trust (XBI) is here too. Its reason reads: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “healthcare” (pharma and health) in this story
Dates and price levels for Select Sector Spdr Tr (XLV)
XLF traded between 52.82 and 56.03 across 20 sessions. The latest close on file is 55.07.
How strong the case is around Select Sector Spdr Tr (XLV)
46 out of 100Price not final
“CVS to Split Off Drugstore Business, Ending the Bigger-Is-Better Era for Healthcare Conglomerates” scores 46 out of 100. The score uses 1 sources, and 8 linked companies. The price is not final yet.